Clinical trials: Hypoglycemic Syndrome
- Condition Hypoglycemic Syndrome
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Diabetes, Diabetes Mellitus, Type 1
A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes
This study is conducted globally. The aim of this study is to describe the proportion of patients with hypoglycaemic episodes and estimate the incidence of various types of hypoglycaemia in the retrospective and prospective…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02306681
- Testing
- No treatment given
- Where
- 8 sites in Bangladesh, Colombia and 6 more
- Volunteers
- 7,315 people
- Sponsor
- Novo Nordisk A/S
Congenital Hyperinsulinism
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to…
- Trial name
- NCT04172441
- Testing
- dasiglucagon
- Where
- 6 sites in United States, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Zealand Pharma
Diabetes Mellitus, Type 1
Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial
A 6-week crossover study will compare PLGS to SAP outcomes in adults and youth > 6 years old with type 1 diabetes (T1D).
- Trial name
- NCT03195140
- Testing
- Predictive Low Glucose Suspend
- Where
- 4 sites in United States
- Volunteers
- 103 people
- Sponsor
- Tandem Diabetes Care, Inc.
Congenital Hyperinsulinism
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC).
- Trial name
- NCT04732416
- Testing
- HM15136
- Where
- 7 sites in United States, Germany and 3 more
- Volunteers
- 17 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Glycogen Storage Disease Type III
Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III
The primary objective of this study is to evaluate the incidence of hypoglycemia in adult and pediatric participants with glycogen storage disease type III (GSD III).
- Trial name
- NCT05196165
- Testing
- No Intervention
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 14 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Diabetes
Continuous Monitoring and Control of Hypoglycemia
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
- Trial name
- COACH (NCT03340831)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- 25 sites in United States
- Volunteers
- 1,388 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes Mellitus
Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia
The purpose of the study is to compare the glycemic control during and following aerobic exercise using either an open or closed-loop insulin delivery system.
- Trial name
- ePID-03 (NCT00831389)
- Testing
- Closed Loop
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D.
- Trial name
- NCT06588504
- Testing
- Dasiglucagon, Glucagon
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Congenital Hyperinsulinism
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent…
- Trial name
- NCT02937558
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Xeris Pharmaceuticals
Congenital Hyperinsulinism
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 (NCT04172441) or ZP4207-17109 (NCT03777176)…
- Trial name
- NCT03941236
- Testing
- dasiglucagon
- Where
- 10 sites in United States, Germany and 2 more
- Volunteers
- 42 people
- Sponsor
- Zealand Pharma
Diabetes, Diabetes Mellitus, Type 1
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
This study is conducted in Europe. The aim of the study is to gather information about hypoglycaemia (low blood glucose) among patients with Type 1 or Type 2 diabetes mellitus. The study is both retrospective and prospective.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01696266
- Testing
- No treatment given
- Where
- 24 sites in Argentina, Austria and 22 more
- Volunteers
- 29,304 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing
To compare the percentage of subjects with a glucose measurement < than or = to 56 mg/dL at any point of the 8-point glucose profiles during 3 consecutive days before vs.
- Trial name
- NCT00609895
- Testing
- INSULIN GLARGINE
- Where
- Mexico
- Volunteers
- 22 people
- Sponsor
- Sanofi
Hypoglycemia, Type 1 Diabetes
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use.
- Trial name
- NCT05378672
- Testing
- Dasiglucagon
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Zealand Pharma
Diabetes Mellitus, Type 1, Hypoglycemia
T1 Diabetes Hypoglycemia Prevention Pilot
A single center pilot study assessing the Vigilant Diabetes Management System for the prevention of recurrent mild to moderate hypoglycemia in type I diabetes patients.
- Trial name
- NCT02682940
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study.
- Trial name
- NCT02402933
- Testing
- Nasal Glucagon
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Type I Diabetes
Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device
This study observes the continuous measurement of breathing patterns, heart rate, restlessness, and tremor in sleep using the EarlySense ES 16 device as a tool in the management of hypoglycemia in pediatric type I diabetes…
- Trial name
- NCT00361608
- Testing
- EarlySense ES 16
- Where
- Israel
- Sponsor
- EarlySense Ltd.
Congenital Hyperinsulinism
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
The objective of the trial is to evaluate the efficacy and safety of dasiglucagon administered as a subcutaneous (SC) infusion in reducing hypoglycemia in children with CHI.
- Trial name
- NCT03777176
- Testing
- Dasiglucagon, Standard of Care
- Where
- 10 sites in United States, Germany and 2 more
- Volunteers
- 32 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years.
- Trial name
- RescuiNGkids (NCT04992312)
- Testing
- Glucagon Nasal Powder [Baqsimi]
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use…
- Trial name
- RECORD-IQ (NCT07211126)
- Testing
- t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
- Where
- 25 sites in France
- Volunteers
- 350 people
- Sponsor
- Tandem Diabetes Care, Inc.
Hypoglycemia
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when administered as a rescue therapy…
- Trial name
- NCT03667053
- Testing
- dasiglucagon, GlucaGen HypoKit
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 42 people
- Sponsor
- Zealand Pharma